Ron Lahav has a diverse work experience in the biotechnology industry. Ron is currently the Managing Director at NIBN, where they oversee the operations of the organization. Prior to that, they co-founded AltA-ZuZ Therapeutics, a company focused on developing a novel inhibitor for autoimmune diseases. Ron also served as the Executive Director of Research and Development at NIBN, where they managed multiple research projects and scientists in various fields. Ron has held leadership roles at SpliSense, ART BioScience Ltd, and Quiet Therapeutics, where they played a crucial role in the development and commercialization of therapeutics. Ron has also worked at Quark Pharmaceuticals, AnorMED, and Princeton University in earlier stages of their career.
Ron Lahav earned their PhD in Environmental Microbiology from Ben Gurion University of the Negev from 1997 to 2002. Following that, they pursued a post-doctorate in Molecular Biology at Princeton University from 2002 to 2005.
This person is not in any teams
This person is not in any offices
NIBN | The National Institute for Biotechnology in the Negev
The National Institute for Biotechnology in the Negev Ltd. is a research Institute that serves as an accelerator for technologies originating from Ben-Gurion University of the Negev, and located in the University campus. The institute's goal is to promote applied, innovative and groundbreaking research in the field of biotechnology, while leading the proof of scientific concept and commercialization. The research at the Institute focuses on areas that are at the forefront of the development of the pharma industry: Cancer, Degenerative diseases, Autoimmune and Metabolic diseases, Infectious diseases, Genetic diseases, as well as, applied Biotechnological research in the fields of AgBio. The research at the Institute has yielded over 900 publications in leading scientific journals, more than 60 patent families and a number of commercializations, mainly, licensing breakthrough technologies to third parties for further development and as a basis for establishing new startups.